Baricitinib plus Standard of Care for Hospitalized Adults with COVID-19
Data Availability
Eli Lilly and Company provides access to all individual participant data collected during the trial, after anonymization, with the exception of pharmacokinetic or genetic data. Data are available to request 6 months after the indication studied has been approved in the US and EU and after the trial is completed, whichever is later. No expiration date of data requests is currently set once data are made available. Access is provided after a proposal has been approved by an independent review committee identified for this purpose and after receipt of a signed data sharing agreement. Data and documents, including the study protocol, statistical analysis plan, clinical study report, blank or annotated case report forms, will be provided in a secure data sharing environment. For details on submitting a request, see the instructions provided at www.vivli.org.
Subject Area
- Addiction Medicine (399)
- Allergy and Immunology (710)
- Anesthesia (201)
- Cardiovascular Medicine (2944)
- Dermatology (249)
- Emergency Medicine (440)
- Epidemiology (12750)
- Forensic Medicine (12)
- Gastroenterology (828)
- Genetic and Genomic Medicine (4586)
- Geriatric Medicine (419)
- Health Economics (729)
- Health Informatics (2918)
- Health Policy (1069)
- Hematology (389)
- HIV/AIDS (924)
- Medical Education (426)
- Medical Ethics (115)
- Nephrology (469)
- Neurology (4359)
- Nursing (236)
- Nutrition (639)
- Oncology (2271)
- Ophthalmology (647)
- Orthopedics (258)
- Otolaryngology (325)
- Pain Medicine (279)
- Palliative Medicine (83)
- Pathology (501)
- Pediatrics (1197)
- Primary Care Research (496)
- Public and Global Health (6944)
- Radiology and Imaging (1529)
- Respiratory Medicine (915)
- Rheumatology (438)
- Sports Medicine (385)
- Surgery (489)
- Toxicology (60)
- Transplantation (212)
- Urology (181)